Prostate cancer antigen 3 (PCA3) RNA detection in blood and tissue samples for prostate cancer diagnosis

Clinical Chemistry and Laboratory Medicine

Volumn 51, Issue 4, 2013, Pages 881-887

  Neves, Adriana F ^a   Dias Oliveira, Jaqueline D Dores ^b   Araújo, Thaise G ^c   Marangoni, Karina ^c   Goulart, Luiz R ^c,d  

^a FEDERAL UNIVERSITY OF GOIÁS   (Brazil)

^b UNIVERSIDADE FEDERAL DO TOCANTINS   (Brazil)

^c FEDERAL UNIVERSITY OF UBERLÂNDIA   (Brazil)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Benign hyperplasia; Gene expression; Peripheral blood; Prostate cancer; Prostate cancer antigen 3; Prostatic tissue; RT PCR assay

Indexed keywords

PROSTATE ANTIGEN; PROSTATE CANCER ANTIGEN 3; RNA; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIGEN DETECTION; ARTICLE; BLOOD; BLOOD LEVEL; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE; PROSTATE CANCER; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; TISSUE LEVEL;

AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS, RNA;

EID: 84882257336     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2012-0392     Document Type: Article

References (24)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics CA cancer. J Clin 2011;61:69-90.
2. Buhmeida A, Pyrh ö nen S, Laato M, CollanY. Prognostic factors in prostate cancer. Diagn Pathol 2006;1:4.
3. Bickers B, Aukim-Hastie C. New molecular biomarkers for the prognosis and management of prostate cancer-the post PSA era. Anticancer Res 2009;29:3289-98.
4. Strittmatter F, Stieber P, Nagel D, F ü llhase C, Walther S, Stief CG, et al. Detection of prostate cancer with complexed PSA and complexed/total PSA ratio-is there any advantage? Eur J Med Res 2011;16:445-50.
5. Chou R, Croswell JM, Dana T, Bougatsos C, Blazina I, Fu R, et al. Screening for prostate cancer: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2011;155:762-71.
6. Salami SS, Schmidt F, Laxman B, Regan MM, Rickman DS, Scherr D, et al. Combining urinary detection of TMPRSS2: ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer. Urol Oncol 2011. Epub ahead of print 19 May 2011. DOI:10.1016/j.urolonc.2011.04.001.
7. Bussemakers MJ, van Bokhoven A, Verhaegh GW, Smit FP, Karthaus HF, Schalken JA, et al. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res 1999;59:5975-9.
8. Schalken JA, Hessels D, Verhaegh G. New targets for therapy in prostate cancer: differential display code 3 (DD3(PCA3)), a highly prostate cancer-specific gene. Urology 2003;62:34-43.
9. Kok JB, Verhaegh GW, Roelofs RW, Hessels D, Kiemeney LA, Aalders TW, et al. DD3(PCA3), a very sensitive and specific marker to detect prostate tumors. Cancer Res 2002;62: 2695-8.
10. Hessels D, Klein Gunnewiek JM, van Oort I, Karthaus HF, van Leenders GJ, van Balken B, et al. DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol 2003;44:8-15.
11. Hessels D, van Gils MP, van Hooij O, Sander A, Jannink SA, Witjes JA, et al. Predictive value of PCA3 in urinary sediments in determining clinico-pathological characteristics of prostate cancer. Prostate 2010;70:10-6.
12. Fontenete S, Silva J, Teixeira AL, Ribeiro R, Bastos E, Pina F, et al. Controversies in using urine samples for prostate cancer detection: PSA and PCA3 expression analysis. Int Braz J Urol 2011;37:719-26.
13. Oliveira JD, Goulart LR, Waldesse PO, Meola J, Neves AF. DD3 gene expression in peripheral blood of patients with prostate cancer and with benign prostate hyperplasia as a molecular diagnostic. Eur Urol 2003;2(Suppl):S102.
14. V ä än änen RM, Rissanen M, Kauko O, Junnila S, V äisänen V, Nurmi J, et al. Quantitative real-time RT-PCR assay for PCA3. Clin Biochem 2008;41:103-8.
15. Jost M, Day JR, Slaughter R, Koreckij TD, Gonzales D, Kinnunen M, et al. Molecular assays for the detection of prostate tumor derived nucleic acids in peripheral blood. Mol Cancer 2010;9:174.
16. Llanes L, Ferruelo A, P á ez A, G ó mez JM, Moreno A, Berenguer A. The clinical utility of the prostate specific membrane antigen reverse-transcription/polymerase chain reaction to detect circulating prostate cells: an analysis in healthy men and women. Br J Urol Int 2002;89:882-5.
17. Mart ínez-Piñeiro L, Rios E, Mart ínez-Gomariz M, Pastor T, de Cabo M, Picazo ML, et al. Molecular staging of prostatic cancer with RT-PCR assay for prostate-specific antigen in peripheral blood and lymph nodes: comparison with standard histological staging and immunohistochemical assessment of occult regional lymph node metastases. Eur Urol 2003;43:342-50.
18. Kurek R, Nunez G, Tselis N, Konrad L, Martin T, Roeddiger S, et al. Prognostic value of combined " triple " -reverse transcription-PCR analysis for prostate-specific antigen, human kallikrein 2, and prostate-specific membrane antigen mRNA in peripheral blood and lymph nodes of prostate cancer patients. Clin Cancer Res 2004;10:5808-14.
19. Mitsiades CS, Lembessis P, Sourla A, Milathianakis C, Tsintavis A, Koutsilieris M. Molecular staging by RT-PCR analysis for PSA and PSMA in peripheral blood and bone marrow samples is an independent predictor of time to biochemical failure following radical prostatectomy for clinically localized prostate cancer. Clin Exp Metastasis 2004;21:495-505.
20. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol chloroform extraction. Anal Biochem 1987;62:156-9.
21. Tao Z, Shen M, Zheng Y, Mao X, Chen Z, Yin Y, et al. PCA3 gene expression in prostate cancer tissue in a Chinese population: quantification by real-time FQ-RT-PCR based on exon 3 of PCA3. Exp Mol Pathol 2010;89:58-62.
22. Neves AF, Ara ú jo TG, Biase WK, Meola J, Alc â ntara TM, Freitas DG, et al. Combined analysis of multiple mRNA markers by RT-PCR assay for prostate cancer diagnosis. Clin Biochem 2008;41:1191-8.
23. George J, Gondi CS, Dinh DH, Gujrati M, Rao JS. Restoration of tissue factor pathway inhibitor-2 in a human glioblastoma cell line triggers caspase-mediated pathway and apoptosis. Clin Cancer Res 2007;13:3507-17.
24. Ruijter E, van de Kaa C, Miller G, Ruiter D, Debruyne F, Schalken J. Molecular genetics and epidemiology of prostate carcinoma. Endocr Rev 1999;20:22-45